Tonix Pharmaceuticals to Present at the MIXiii Biomed Conference in Israel
NEW YORK, May 20, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced that its CEO, Seth Lederman, MD, will be speaking at MIXiii Biomed, an Israel Innovation Conference, to be held in Tel Aviv, Israel on Thursday, May 22nd. Dr. Lederman's talk will focus on Tonix's pharmaceutical development programs for the management of fibromyalgia (FM) and post-traumatic stress disorder (PTSD).
"We are honored to be included among the companies presenting at MIXIiii this year," said Seth Lederman, MD, president and chief executive officer of Tonix. "Given growing recognition of the impact of FM and PTSD on societies worldwide, MIXiii is an excellent venue in which to discuss our innovations in developing therapies for these difficult-to-treat conditions."
Dr. Lederman's talk, titled, "Is Sleep Disturbance an Achilles' Heel of the Fibromyalgia and PTSD Monsters?" will be held at 3:30 pm local time at the Israel Trade Fairs & Convention Center.
About the MIXiii Conference
The MIXiii (Israel Innovation International) Conference, in association with IATI Israel Advanced Technology Industries and the Office of the Chief Scientist of Israeli Ministry of Economy, will be the first in the world where biomed and high-tech will join hands in a unique and exciting new international conference format. The conference will take place at the Tel Aviv Fairgrounds on May 20-22, 2014. To learn more, please visit www.mixiii.com.
About Tonix Pharmaceuticals Holding Corp.
Tonix develops innovative prescription medicines for common and complex disorders of the central nervous system. Fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache are characterized by inadequate treatment options, dissatisfaction expressed among patients and physicians, and significant expense burden. Tonix is currently conducting the first anticipated pivotal trial of TNX-102 SL in FM, the BESTFIT trial (BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy). Tonix expects to begin clinical development of TNX-102 SL in PTSD in the third quarter of 2014. With TNX-102 SL, Tonix approaches the treatment of people suffering from FM and PTSD by targeting their inability to obtain restorative sleep. TNX-201 is in development for episodic tension-type headache, and Tonix expects to begin clinical studies of TNX-201 in the fourth quarter of 2014. To learn more, please visit www.tonixpharma.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on March 28, 2014 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.
CONTACT: Tonix Pharmaceuticals Holding Corp. Leland Gershell Chief Financial Officer (212) 980-9155 x104 firstname.lastname@example.org Public Relations: JQA Partners, LLC Jules Abraham (917) 885-7378 email@example.comSource: Tonix Pharmaceuticals Holding, Inc.
Released May 20, 2014